LEAD alum ArgusEye, which originated in research at Linköping University, has secured a EUR 3.3 million funding round. The company will now accelerate the development and commercialization of its platform for real-time monitoring of bioprocesses.
The round is backed by existing investors such as Voima Ventures and Eir Ventures, as well as a new investor in the form of Impilo Partners Invest.
– This funding allows us to accelerate both technology development and commercial expansion,” says Sofia Håkansson Buch, CEO of ArgusEye in a press release.
The capital will be used to further develop ArgusEye’s patented Auga™ platform, which enables real-time analysis directly in the bioprocess. The technology provides continuous monitoring and control of production, which can shorten lead times and increase efficiency in biomanufacturing.
ArgusEye originated from research at Linköping University and was founded in 2017. Since then, the company has grown with a multidisciplinary team in biosensors, biochemistry, and hardware and software development. Today, the company works with several leading global pharmaceutical companies and now plans to further expand its international customer base.
Read the press release here.
